Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF-IR: Insulin Sensitivity in Healthy Volunteers on TAF-Containing ART
NCT03092206Phase 1Completed
- Sponsor
- Technical University of Munich
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Technical University of Munich. Primary endpoint: Changes in insulin sensitivity at 14 days. Started Apr 2017; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03092206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092206.